Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients

Table 1

The primer and probe sequences for microarray.

Targeted gene	Primer/Probe	Sequencing (5’-3’)
CYP450	2C192-F	CAGAGCTTGGCATATTGTATCT
	2C192-R	GATCAGGAAGCAATCAATAAA
	2C193-F	GATCAGCAATTTCTTAACTTGATGGA
	2C193-R	TTCAAAAATGTACTTCAGGGCTTGGT
	2C192W	ATTATTTCCCGGGAACCCAT
	2C192M	TTATTTCCCAGGAACCCAT
	2C193W	TAAGCACCCCCTGGATCCAGGT
	2C193M	GTAAGCACCCCCTGAATCCAGG
23S rRNA	H. PYLORI23S-F	ATTCAGTGAAATTGTAGTGGAGGTGA
	H. PYLORI23S-R	CCATTAGCAGTGCTAAGTTGTAGTA
	42W43W	CGGCAAGACGGAAAGACCCC
	42M43W	CGGCAAGACGGGAAGACCCC
	42W43M	GGCAAGACGGAGAGACCCCG
	42M43M	CGGCAAGACGGGGAGACCCC
gyrA	GF240	GGGTGATGTGATTGGTAAATACCAC
	GR319	TTCGAAAAATCTTGCGCCATTCTC
	87WT	CCATGGCGATAATGCGGTTTA
	87WC	CCATGGCGATAACGCGGTTTA
	87MA	CCATGGCGATAAAGCGGTTTA
	87MG	CCATGGCGATAAGGCGGTTTA
	91W	GCGGTTTATGATGCRCTAG
	91MG	TGCGGTTTATGGTGCRCTAG
	91MA	TGCGGTTTATAATGCRCTAT
	Quality control	TTTTTTTTTTTTTTTTTTTT

F: forward primer; R: reverse primer; reverse primers used for microarray have biotin conjugated at 5’-ends; W: wild genotype probe; M: mutant genotype probe, an oligonucleotide of 12 T’s with an amino-labeled 3’-end was conjugated to the 3’-ends of all probes; an oligonucleotide of 20 T’s with an amino-labeled 3’-end, biotin-labeled 5’-end was used as microarray quality control.